Key Points
- Michael Feld, EVP of Becton, Dickinson, sold 75 shares on December 1 at an average price of $193.36 for $14,502, leaving him with 16,580 shares (a 0.45% reduction in his stake).
- BDX raised its quarterly dividend to $1.05 (from $1.04), payable December 31 with record/ex-dividend date December 8, representing a $4.20 annualized payout and a 2.2% yield.
- Street view and valuation: MarketBeat shows a consensus "Hold" with an average target of $204.45; the stock trades near $190.51, has a $54.38B market cap and a P/E of 32.68 (52-week range $162.29–$251.99).
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the firm's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $193.36, for a total value of $14,502.00. Following the transaction, the executive vice president owned 16,580 shares of the company's stock, valued at $3,205,908.80. The trade was a 0.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Michael Feld also recently made the following trade(s):
- On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $186.01, for a total transaction of $10,602.57.
- On Friday, September 26th, Michael Feld sold 58 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.03, for a total transaction of $10,499.74.
Becton, Dickinson and Company Trading Down 0.7%
Shares of NYSE BDX opened at $190.51 on Wednesday. The firm's 50 day moving average price is $187.68 and its 200-day moving average price is $183.47. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market cap of $54.38 billion, a PE ratio of 32.68, a P/E/G ratio of 1.77 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. This is an increase from Becton, Dickinson and Company's previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 71.36%.
Hedge Funds Weigh In On Becton, Dickinson and Company
A number of institutional investors and hedge funds have recently made changes to their positions in the business. SOA Wealth Advisors LLC. increased its holdings in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 95 shares during the last quarter. Activest Wealth Management grew its position in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $25,000. Saudi Central Bank bought a new position in Becton, Dickinson and Company in the 1st quarter worth $26,000. Finally, Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on BDX. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Stifel Nicolaus lowered their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Jefferies Financial Group reduced their price target on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday, November 7th. Wall Street Zen cut shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada dropped their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a "sector perform" rating on the stock in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $204.45.
Check Out Our Latest Stock Report on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
